A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

• Status: Completed
• Trial end date: 2014-11-17
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
• Treatments: Lurasidone Hydrochloride

Criteria

Inclusion Criteria:

• Patient meets DSM-IV-TR criteria for schizophrenia.

• Patient is aged 18 through 74 years at informed consent.

• Patient understands the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study

Exclusion Criteria:

• Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus.

• Patient has Parkinson's disease.

• Patient has a history or complication of malignancy.